Table 1.
Demographic and Clinical Characteristics of Analyzed Patients
| Characteristic | mFF6 (n = 1,338) |
mFF6 + Bev (n = 1,334) |
Total (N = 2,672) |
|||
|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |
| Age, years | ||||||
| < 50 | 332 | 24.8 | 342 | 25.6 | 674 | 25.2 |
| 50-59 | 447 | 33.4 | 435 | 32.6 | 882 | 33.0 |
| 60-69 | 347 | 25.9 | 367 | 27.5 | 714 | 26.7 |
| ≥ 70 | 212 | 15.8 | 190 | 14.2 | 402 | 15.0 |
| Sex | ||||||
| Female | 673 | 50.3 | 668 | 50.1 | 1,341 | 50.2 |
| Male | 665 | 49.7 | 666 | 49.9 | 1,331 | 49.8 |
| Ethnicity | ||||||
| White | 1,172 | 87.6 | 1,160 | 87.0 | 2,332 | 87.3 |
| Black | 101 | 7.6 | 114 | 8.6 | 215 | 8.0 |
| Other | 50 | 3.7 | 43 | 3.2 | 93 | 3.5 |
| Multiracial | 2 | 0.2 | 1 | 0.1 | 3 | 0.1 |
| Unknown | 13 | 1.0 | 16 | 1.2 | 29 | 1.1 |
| ECOG performance | ||||||
| 0 = fully active | 1,089 | 81.4 | 1,075 | 80.6 | 2,164 | 81.0 |
| 1 = no strenuous activity | 249 | 18.6 | 259 | 19.4 | 508 | 19.0 |
| Nodal stage | ||||||
| N0 = node negative | 332 | 24.8 | 334 | 25.0 | 666 | 24.9 |
| N1 = 1-3 positive nodes | 611 | 45.7 | 607 | 45.5 | 1,218 | 45.6 |
| N2 = ≥ 4 positive nodes | 395 | 29.5 | 393 | 29.5 | 788 | 29.5 |
Abbreviations: mFF6, modified FOLFOX6 (ie, infusional/bolus fluorouracil, leucovorin, and oxaliplatin); Bev, bevacizumab; ECOG, Eastern Cooperative Oncology Group.